Imperial spinout Siftr Bio aims to improve precision of ADC cancer drugs
A new Imperial spinout aims to improve the performance of an emerging class of cancer treatments known as antibody-drug conjugates or ADCs.
Exploring Molecular Glues: Insights from the Sir Geoffrey Wilkinson Lecture
The Department of Chemistry welcomed Professor Stuart Schreiber, who discussed molecular glues and their transformative potential in drug discovery.
Institute for Molecular Science and Engineering (IMSE) Research Showcase 2024
IMSE showcased how integrating expertise across diverse academic disciplines and with external stakeholders helps solve grand challenges.
New tool could transform study of cells and help find new drug targets
A new tool from Imperial and Molecular Dimensions could help biologists rapidly uncover valuable insights into the proteins found in cell membranes.
Imperial and Crick cancer drug spinout raises £90m to begin clinical development
Myricx Bio is bringing new therapeutic possibilities to the highly promising area of antibody-drug conjugates for treating cancer.
Mathematics PhD student wins major science communication competition
Kevin Michalewicz from the Department of Mathematics has won the TakeAIM Competition, an annual competition hosted by the Smith Institute.
New synthesis platform allows for rapid cancer drug synthesis and testing
Imperial researchers have developed a new platform for the synthesis, analysis and testing of new compounds which may one day treat cancer
Feature
Eight things we learned about commercialising medical research at AYCI 2024
We learnt why you should channel Mary Somerville, how timing can make or break a startup, and other lessons from experts at All You Can Innovate 2024.
Impact of artificial intelligence on AMR: Common themes and challenges
Researchers gather to explore visions, themes & challenges around the use of Artificial Intelligence (AI) to tackle antimicrobial resistance (AMR).
New class of cancer and immunology drug targets mapped with new tagging system
Researchers have used ‘click chemistry’ to map the role of a group of enzymes that could be key for developing new medicines in cancer and immunology.
